Kenvue (NYSE:KVUE) Issues FY 2025 Earnings Guidance

Kenvue (NYSE:KVUE) updated its FY 2025 earnings guidance on Monday. The company provided EPS guidance of 1.000-1.050 for the period, compared to the consensus EPS estimate of 1.010. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. The Goldman Sachs Group lowered their target price on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. Redburn Partners set a $22.00 target price on Kenvue in a report on Friday, September 26th. Johnson Rice reaffirmed a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a report on Friday, October 24th. Finally, Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $20.17.

Kenvue Trading Up 1.1%

Shares of NYSE KVUE opened at $14.40 on Monday. Kenvue has a one year low of $14.02 and a one year high of $25.17. The firm has a market capitalization of $27.63 billion, a PE ratio of 19.45, a PEG ratio of 2.07 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $17.21 and a two-hundred day moving average price of $20.50.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.During the same quarter last year, the firm posted $0.28 earnings per share. Kenvue’s quarterly revenue was down 3.5% on a year-over-year basis. As a group, analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 5.8%. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Institutional Investors Weigh In On Kenvue

A number of institutional investors have recently bought and sold shares of KVUE. State of Wyoming acquired a new stake in shares of Kenvue during the 2nd quarter valued at about $159,000. EP Wealth Advisors LLC acquired a new stake in Kenvue in the 2nd quarter worth approximately $241,000. Voleon Capital Management LP acquired a new stake in Kenvue in the 2nd quarter worth approximately $309,000. B. Riley Wealth Advisors Inc. acquired a new stake in Kenvue in the 2nd quarter worth approximately $439,000. Finally, Headlands Technologies LLC acquired a new stake in Kenvue in the 2nd quarter worth approximately $648,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.